| Defining the activated fibroblast population in lung fibrosis using single-cell sequencing R Peyser, S MacDonnell, Y Gao, L Cheng, Y Kim, T Kaplan, Q Ruan, ... American journal of respiratory cell and molecular biology 61 (1), 74-85, 2019 | 154 | 2019 |
| Cyclophilin D gene ablation protects mice from ischemic renal injury K Devalaraja-Narashimha, AM Diener, BJ Padanilam American Journal of Physiology-Renal Physiology 297 (3), F749-F759, 2009 | 128 | 2009 |
| Poly (ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury J Zheng, K Devalaraja-Narashimha, K Singaravelu, BJ Padanilam American Journal of Physiology-Renal Physiology 288 (2), F387-F398, 2005 | 124 | 2005 |
| PARP-1 inhibits glycolysis in ischemic kidneys K Devalaraja-Narashimha, BJ Padanilam Journal of the American Society of Nephrology 20 (1), 95-103, 2009 | 93 | 2009 |
| PARP1 deficiency exacerbates diet-induced obesity in mice K Devalaraja-Narashimha, BJ Padanilam Journal of endocrinology 205 (3), 243, 2010 | 77 | 2010 |
| Urinary single-cell profiling captures the cellular diversity of the kidney A Abedini, YO Zhu, S Chatterjee, G Halasz, K Devalaraja-Narashimha, ... Journal of the American Society of Nephrology 32 (3), 614-627, 2021 | 72 | 2021 |
| Poly (ADP-ribose) polymerase-mediated cell injury in acute renal failure K Devalaraja-Narashimha, K Singaravelu, BJ Padanilam Pharmacological research 52 (1), 44-59, 2005 | 66 | 2005 |
| TIGAR regulates glycolysis in ischemic kidney proximal tubules J Kim, K Devalaraja-Narashimha, BJ Padanilam American Journal of Physiology-Renal Physiology 308 (4), F298-F308, 2015 | 53 | 2015 |
| PERP, a p53 proapoptotic target, mediates apoptotic cell death in renal ischemia K Singaravelu, K Devalaraja-Narashimha, B Lastovica, BJ Padanilam American Journal of Physiology-Renal Physiology 296 (4), F847-F858, 2009 | 36 | 2009 |
| Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease A Ozen, N Kasap, I Vujkovic-Cvijin, R Apps, F Cheung, E Karakoc-Aydiner, ... Nature immunology 22 (2), 128-139, 2021 | 28 | 2021 |
| Cyclophilin D deficiency prevents diet-induced obesity in mice K Devalaraja-Narashimha, AM Diener, BJ Padanilam FEBS letters 585 (4), 677-682, 2011 | 26 | 2011 |
| Rationale and design of the transformative research in diabetic nephropathy (TRIDENT) study RR Townsend, P Guarnieri, C Argyropoulos, S Blady, CM Boustany-Kari, ... Kidney international 97 (1), 10-13, 2020 | 24 | 2020 |
| Spatially resolved human kidney multi-omics single cell atlas highlights the key role of the fibrotic microenvironment in kidney disease progression A Abedini, J Levinsohn, KA Klötzer, B Dumoulin, Z Ma, J Frederick, ... bioRxiv, 2022.10. 24.513598, 2022 | 16 | 2022 |
| Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates K Devalaraja-Narashimha, C Huang, M Cao, YP Chen, A Borodovsky, ... PLoS One 17 (6), e0269749, 2022 | 11 | 2022 |
| Humanized C3 mouse: a novel accelerated model of C3 glomerulopathy K Devalaraja-Narashimha, K Meagher, Y Luo, C Huang, T Kaplan, ... Journal of the American Society of Nephrology 32 (1), 99-114, 2021 | 8 | 2021 |
| Pozelimab, a human antibody against complement factor C5, demonstrates robust inhibition of alternative complement activity both in normal human serum and in phase I normal … K Devalaraja-Narashimha, YG Ni, C Huang, MD Wang, U Chaudhari, ... Blood 134, 2278, 2019 | 8 | 2019 |
| Association of complement pathways with COVID-19 severity and outcomes K Devalaraja-Narashimha, PJ Ehmann, C Huang, Q Ruan, ... Microbes and Infection 25 (4), 105081, 2023 | 7 | 2023 |
| Humanized model of kidney and liver disorders K Devalaraja-Narashimha, L Morton, Y Luo, C Huang, K Meagher, ... US Patent 10,765,762, 2020 | 5 | 2020 |
| Alternative Pathway Complement Activation and Low Circulating Inhibitors Associate With Severity and Mortality in COVID-19 and Non-COVID Sepsis NJ Meyer, K Devalaraja-Narashimha, K Laudanski, P Ehmann, ... A103. DYSREGULATED PATHWAYS IN SEPSIS AND LUNG INJURY: SEARCHING FOR …, 2024 | | 2024 |
| EFFECTS OF REGN5381, A NATRIURETIC PEPTIDE RECEPTOR 1 AGONIST ANTIBODY, IN HYPERTENSIVE MOUSE MODELS AND MILDLY HYPERTENSIVE BUT OTHERWISE HEALTHY ADULTS IN A PHASE 1 FIRST-IN … AP Kithcart, K Devalaraja-Narashimha, L Liu, X Jin, J Torello, D Zhang, ... Journal of the American College of Cardiology 83 (13_Supplement), 1706-1706, 2024 | | 2024 |
